SCHEDULE 13G/A: BlackRock Discloses 10.6% Stake in Anika Therapeutics
Beneficial Ownership Disclosure
BlackRock, Inc. has filed an amended Schedule 13G, reporting a beneficial ownership of 10.6% of Anika Therapeutics Inc.'s common stock as of December 31, 2024.
Summary
- BlackRock, Inc. reported beneficial ownership of 1,557,882 shares of Anika Therapeutics Inc. common stock.
- This represents 10.6% of the total outstanding common shares of Anika Therapeutics Inc.
- BlackRock, Inc. holds sole voting power over 1,516,035 shares and sole dispositive power over 1,557,882 shares.
- The filing is an Amendment No. 6 to a Schedule 13G, indicating an update to a previously reported ownership position.
- The ownership position is reported as of December 31, 2024.
- BlackRock, Inc. is filing as a parent holding company, with several subsidiaries identified as holding the securities, including BlackRock Investment Management, LLC, which beneficially owns 5% or more of the outstanding shares.
Sentiment
Score: 5
Explanation: A Schedule 13G filing is a factual disclosure of ownership and typically carries a neutral sentiment, as it does not convey positive or negative operational or financial news about the issuer.
Future Outlook
NA
Industry Context
This filing is a standard disclosure by a large institutional investor (BlackRock) regarding its significant stake in a healthcare/biotechnology company (Anika Therapeutics). It reflects BlackRock's portfolio management activities rather than specific industry trends, though Anika Therapeutics operates in the orthopedic and regenerative medicine sector.
Stakeholder Impact
- Primarily impacts shareholders by providing transparency on significant institutional ownership, which can influence market perception and liquidity.
- Provides insight into the holdings of a major institutional investor, BlackRock, for other market participants.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of the previously revoked Power of Attorney. |
| 2024-12-31 | Date of the event which requires filing of this statement (ownership position determination date). |
| 2025-01-21 | Date of the new Power of Attorney. |
| 2025-02-05 | Date of filing of this Schedule 13G Amendment No. 6. |
Keywords
Anika Therapeutics Inc, BlackRock Inc, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor, Equity Stake, Healthcare Sector, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.